Literature DB >> 31455576

Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures.

Jason Taam1, Qi Joy Yang2, K Sandy Pang2, Paul Karanicolas3, Stephen Choi4, Marcin Wasowicz5, Angela Jerath6.   

Abstract

Tranexamic acid reduces blood loss and transfusion requirements with no significant thrombotic adverse effects. Postoperative seizures have been seen in cardiac surgical patients in association with patient (advanced age, underlying neurologic disease, chronic kidney disease); surgical (open cardiac procedures, long bypass times); and drug (high tranexamic acid dose) risk factors. Tranexamic acid dosing regimens should be decreased in patients with chronic kidney dysfunction secondary to reduced clearance and drug accumulation. Optimal dosing for cardiac surgical patients has been recommended. Additional research is required to determine dosing regimens in major noncardiac surgery and plasma concentration levels associated with inducing seizures.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Tranexamic acid; antifibrinolytic; blood conservation; cardiac surgery; cardiopulmonary bypass; chronic kidney dysfunction; dose; fibrin; noncardiac surgery; pharmacokinetics; safety; seizures; transfusion; trial

Mesh:

Substances:

Year:  2019        PMID: 31455576     DOI: 10.1053/j.jvca.2019.06.042

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  2 in total

1.  Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery.

Authors:  Jean Wong; Ronald B George; Ciara M Hanley; Chadi Saliba; Doreen A Yee; Angela Jerath
Journal:  Can J Anaesth       Date:  2021-05-15       Impact factor: 5.063

2.  Tranexamic Acid in Shoulder Arthroplasty. A Comprehensive Review.

Authors:  Christos Koutserimpas; Georgios Th Besiris; Dimitrios Giannoulis; Konstantinos Raptis; Konstantinos Vlasis; Konstantinos Dretakis; Kalliopi Alpantaki
Journal:  Maedica (Bucur)       Date:  2021-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.